Form 424B5 - Prospectus [Rule 424(b)(5)]
SEC Accession No. 0001628280-26-065249
Filing Date
2026-10-06
Accepted
2026-10-06 16:41:43
Documents
15

Document Format Files

Seq Description Document Type Size
1 424B5 spyre-final424b5.htm 424B5 425443
2 spyrefilingfees.htm   iXBRL EX-FILING FEES 25235
3 backcover.jpg GRAPHIC 35007
4 pipeline.jpg GRAPHIC 109233
5 prospectus.jpg GRAPHIC 20919
6 spyrelogo.jpg GRAPHIC 7270
  Complete submission text file 0001628280-26-065249.txt   809056

Data Files

Seq Description Document Type Size
19 EXTRACTED XBRL INSTANCE DOCUMENT spyrefilingfees_htm.xml XML 4752
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-297063 | Film No.: 261444591
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)